Top Markets
#1 QuantixAI QuantixAI +36.56%
#2 UnifAI Network UnifAI Network +31.27%
#3 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +31.07%
#4 MowCat MowCat +30.09%
#5 GEKKO GEKKO +26.24%
#6 Prom Prom +25.87%
#7 Wrapped STX (Velar) Wrapped STX (Velar) +22.98%
#8 Kinesis Silver Kinesis Silver +19.70%
#9 MarsCoin MarsCoin +19.60%
#10 Derive Derive +19.26%
Coin of the day
QuantixAI QuantixAI
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Formosa Pharmaceuticals, Inc. Formosa Pharmaceuticals, Inc.

Formosa Pharmaceuticals, Inc.

6838
Rangering i aksjer #20879
Formosa Pharmaceuticals, Inc., a biopharmaceutical firm situated in Taipei... Formosa Pharmaceuticals, Inc., a biopharmaceutical firm situated in Taipei City, Taiwan, is actively engaged in both late-preclinical and early clinical development stages. Its core focus lies in pioneering therapeutic candidates across ophthalmology, oncology, and anti-infective domains. Among its key investigational assets is APP13007, an ophthalmic nanosuspension, currently progressing through Phase III trials for managing post-surgical discomfort and inflammation of the eye. The company's portfolio also encompasses TSY-0110, designed as an antibody-drug conjugate, and TSY-0210, an antibiotic targeting resilient drug-resistant infections. Further compounds under development include APP13002, a topical antibiotic intended for ocular infections like blepharitis, and MPT0E028, a novel pan-histone deacetylase inhibitor being explored for solid malignancies such as hepatomas and colorectal cancer, in addition to lung fibrosis. Additionally, Formosa Pharmaceuticals maintains a collaborative partnership with Eyenovia, Inc., dedicated to advancing innovative ophthalmic treatments. Established in 2010, the company is headquartered in Taiwan's capital.
Aksjekurs
$0.79338575
Sist synkronisert: 2026-07-28
Markedsverdi
$119.78M
Endring (1 dag)
2.67%
Endring (1 år)
-27.61%
Land
TW
Handel Formosa Pharmaceuticals, Inc. (6838)

Kategori

Healthcare
P/E-forhold for Formosa Pharmaceuticals, Inc. (6838)
P/E-forhold per 2026 TTM: 0
Ifølge Formosa Pharmaceuticals, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for Formosa Pharmaceuticals, Inc. fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.